BioMarin Pharmaceutical Inc. (BMRN) Analysts See $-0.09 EPS

October 12, 2017 - By Vivian Park

 BioMarin Pharmaceutical Inc. (BMRN) Analysts See $ 0.09 EPS
Investors sentiment increased to 1.26 in 2017 Q2. Its up 0.06, from 1.2 in 2017Q1. It is positive, as 23 investors sold BioMarin Pharmaceutical Inc. shares while 124 reduced holdings. 51 funds opened positions while 134 raised stakes. 168.09 million shares or 1.78% more from 165.15 million shares in 2017Q1 were reported.
Qvt Fincl L P stated it has 23,799 shares. Morgan Stanley holds 0.01% or 459,268 shares in its portfolio. 9.30 million are owned by Fmr Ltd Liability Company. Macquarie Limited reported 44,152 shares. Prudential Fin holds 0.02% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 145,170 shares. Invesco Limited reported 0.12% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Airain holds 19,770 shares. Northern owns 1.10M shares or 0.03% of their US portfolio. Commonwealth Bank Of has 0% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 976 shares. Great West Life Assurance Can accumulated 144,339 shares or 0.03% of the stock. Seatown Hldg Pte Ltd has 22,000 shares. Amer Natl Insur Tx has 28,095 shares for 0.14% of their portfolio. Fiera Corp accumulated 6,613 shares. Fjarde Ap owns 49,724 shares for 0.09% of their portfolio. Numeric Lc has invested 0.01% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Since April 28, 2017, it had 0 insider buys, and 14 insider sales for $7.91 million activity. $29,215 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares were sold by Ajer Jeffrey Robert. 2,500 shares were sold by Davis George Eric, worth $250,853 on Friday, April 28. $901,300 worth of stock was sold by BIENAIME JEAN JACQUES on Friday, June 2. FUCHS HENRY J also sold $1.35 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. LAWLIS V BRYAN sold $337,500 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, June 16. $687,334 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by Mueller Brian on Friday, April 28.

Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on October, 26. They expect $-0.09 earnings per share, up 30.77 % or $0.04 from last year’s $-0.13 per share. After $-0.05 actual earnings per share reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 80.00 % negative EPS growth. About 295,637 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since October 12, 2016 and is uptrending. It has underperformed by 11.41% the S&P500.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 26 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 18 have Buy rating, 0 Sell and 8 Hold. Therefore 69% are positive. BioMarin Pharmaceutical had 66 analyst reports since August 5, 2015 according to SRatingsIntel. Jefferies maintained the shares of BMRN in report on Thursday, August 24 with “Buy” rating. As per Wednesday, August 5, the company rating was maintained by William Blair. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Perform” rating by Oppenheimer on Wednesday, November 25. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Outperform” rating given on Friday, October 2 by Raymond James. The company was maintained on Tuesday, August 25 by Jefferies. RBC Capital Markets maintained it with “Buy” rating and $145 target in Monday, August 24 report. The rating was upgraded by Goldman Sachs on Monday, March 7 to “Conviction Buy”. The firm has “Hold” rating by Wedbush given on Monday, August 7. The rating was initiated by Oppenheimer on Wednesday, November 18 with “Perform”. The firm has “Neutral” rating by PiperJaffray given on Monday, November 7.

BioMarin Pharmaceutical Inc. is a biotechnology company. The company has market cap of $16.57 billion. The Firm develops and commercializes pharmaceuticals for various diseases and medical conditions. It currently has negative earnings. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates.

More news for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were recently published by:, which released: “BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of …” on October 03, 2017.‘s article titled: “No Ad Com planned for BioMarin’s pegvaliase” and published on September 14, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.